53 results about "Myelin" patented technology

Mapping of myelin water content in white matter may provide important information for early diagnosis of multiple sclerosis and the detection of white matter abnormality in other diseases. It is disclosed here that free induction decay (FID) of each voxel at multiple slice locations is acquired in the brain using an echo-planar spectroscopic imaging (EPSI) pulse sequence. The multi-slice EPSI acquisition is designed to have a short first echo time (˜2 ms) and echo-spacing (˜1 ms) in order to acquire multiple sampling points during the fast decay of the myelin water signal. Multi-compartment analysis is then applied to the FID in each pixel using a 3-pool model of white matter to obtain quantitative maps of the myelin water fraction. Using this technique, the MR data for whole brain mapping of the myelin water can be acquired in less than 10 minutes, making this technique feasible for routine clinical applications.

The present invention relates to methods for treating multiple sclerosis by combining immunotherapy with myelin repair.

The invention provides a cylinder support for repairing spinal cord injury. The cylinder support comprises a collagen sponge cylinder support body. An epidermal growth factor receptor antibody cetuximab is crosslinked with the collagen sponge cylinder support body. Neural stem cells are loaded through the collagen sponge cylinder support body crosslinked with the epidermal growth factor receptor antibody cetuximab so as to promote transplanted neural stem cells to be differentiated into neurons, and the cylinder support which facilitates injured spinal nerve regeneration and functional reconstruction is constructed. The collagen sponge cylinder support body has ultrahigh porosity and provides sufficient space for cell growth. More importantly, controlled-release of the antibody cetuximab can relieve effect myelin protein in a microenvironment after spinal cord injury, promotes transplanted neural stem cells to be differentiated into neurons, restrains transplanted neural stem cells from being differentiated into astroglia cells, and also promotes growth of nerve axons so as to facilitate injured spinal nerve regeneration and functional reconstruction. In addition, the invention further provides an application method of the cylinder support for repairing spinal cord injury.

The invention discloses an ELISA (Enzyme Linked Immunosorbent Assay) kit and application thereof. The ELISA kit comprises a melamine monoclonal antibody and a melamine hapten, wherein the melamine monoclonal antibody is generated by the secretion of melamine monoclonal antibody hybridoma cell strains MAL (Myelin And Lymphocyte) with a preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.3394. The ELISA kit provided by the invention is mainly used for qualitatively or quantitatively detect the content of melamine in the products (especially dairies such as milk, milk powder and the like as well as eggs, feed and the like) eaten by animals or human by the indirect competitive ELISA. By means of the ELISA Kit and the detection method, the requirement on the pretreatment of a sample is low; the pretreatment process of the sample is simple; and mass samples can be rapidly detected at the same time; by utilizing the high-specificity melamine monoclonal antibody, the detection method is convenient, is easy to carry out, and has the characteristics of high specificity, high sensitivity, high precision, high accuracy and the like.

A method of detecting myelin in a subject includes administering to the subject a molecular probe that includes a fluorescent trans stilbene derivative and detecting the amount or distribution of the molecular probe in a tissue of interest of the subject.

The invention relates to an establishment method for a zebrafish multiple sclerosis model, and a method for screening therapeutic medicines for multiple sclerosis or evaluating compound-induced nerve myelin injuries by using the animal model. The establishment method of the zebrafish multiple sclerosis model mainly comprises the following steps of: zebrafish selection, compound treatment, whole zebrafish immunofluorescent staining, image analysis and/or microplate selection, and statistical analysis. The method disclosed by the invention has the advantages of being economic, simple and convenient, rapid, efficient, less in the dosage of compound and the like, can realize a purpose of screening the therapeutic medicines for multiple sclerosis with a high flux in vivo, and is significant for acceleration for the research and development process of the therapeutic medicines for multiple sclerosis, and therapy for patients with multiple sclerosis.

A method for treatment of multiple sclerosis and related disease states. A histamine H2 mimicking agent is administered in an amount which is effective to stimulate production of a cyclic AMP in the body. A phosphodiesterase inhibitor is administered in conjunction with the histamine H2 mimicking agent to conserve the cyclic AMP which is thus produced. It is believed that the increased cyclic AMP levels serve to maintain the patient's myelin against self degeneration. The histamine H2 mimicking agent may be histamine phosphate and the phosphodiesterase inhibitor may be caffeine. The histamine H2 mimicking agent and the phosphodiesterase inhibitor may be mixed in a gel and administered using a transdermal patch.

The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified.

A molecular probe for labeling myelin includes a fluorescent stilbenzene derivative.

Method, system and computer-accessible medium for determining at least one of axonal loss or myelin degradation can be provided. For example, it is possible to receive data based on at least one of a measure of diffusion of an axonal structure or a measure of a density of axons, and determine axonal loss and/or myelin degradation based on the data. The determination can be based on axonal geometry of at least one parallel tube.

The invention discloses a dual-functional collagen scaffold material as well as a preparation method and an application thereof in spinal cord injury repair. The dual-functional collagen scaffold material consists of a nerve regeneration scaffold and a CBD-EGFR-Fab antibody which is bonded with the nerve regeneration scaffold, wherein the CBD-EGFR-Fab antibody comprises a collagen bonding area anda Fab area of an EGFR antibody which is linked to the collagen bonding area. According to the dual-functional collagen scaffold material provided by the invention, in vitro, exogenous neural stem cell bonding can be promoted and differentiation of inhibited neural stem cells towards neurons with the presence of myelin protein can be rescued, and in vivo, spread of the exogenous neural stem cellsfrom a transplantation site can be effectively relieved and a neuronal circuit can be reconstructed by promoting the differentiation of the neural stem cells towards functional neurons, so that the recovery of motor functions after spinal cord injury can be finally promoted.

Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of a combination of therapeutic ordered peptides or one or more modified therapeutic ordered peptide(s) comprising amino acids representing a consensus sequence of a protein identified as a target of the autoimmune T and B cell response. Of particular interest are therapeutic ordered peptides of the target proteins in multiple sclerosis, for example the myelin proteins MBP, MOG, PLP, MAG and cyclic nucleotide phosphodiesterase The therapeutic ordered peptide may consist only of the ordered repeats, or may be extended at either termini by the addition of other D- or L-amino acid residues. For therapy, the therapeutic ordered peptides may be administered topically or parenterally, by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. The subject methods are used for prophylactic or therapeutic purposes. The compositions of the invention may also contain other therapeutically active agents, immunomodulators, immunosuppressants, β-interferon, steroids, statins etc.

Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.

The invention discloses TAT-LBD-PEP fusion protein and application of the TAT-LBD-PEP fusion protein in treatment of central nervous system lesion. The TAT-LBD-PEP fusion protein is combined with myelin inhibiting factors MAG, Nogo-66 and OMgp, accordingly the axon regenerative capacity is promoted through antagonism PirB effect, and the TAT-LBD-PEP fusion protein has the advantages of being high transduction efficiency and easily transmitting a blood-spinal barrier and a blood brain barrier, can transduce targeting to a hurt region and has the enrichment effect on an ischemic region. The problems that additional harm of nervous tissues is caused by the protein injection in a micro-injection mode or other injection modes and macromolecule cannot transmit the blood-spinal barrier and the blood brain barrier are solved, and the shortcoming that corresponding biological concentration cannot be met is overcome, and the targeting is transduced to the ischemic region through a ligand binding domain (LBD). The TAT-LBD-PEP fusion protein can be prepared in large-scale mode, is low in cost and high in activity, and is used for treatment of various brain and spinal cord injury including cerebral ischemia hypoxia, cerebral hemorrhage, cerebral trauma, spinal cord injury and the like and promoting regeneration of nervous tissues and neural functional recovery.

The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells into Schwann cell precursors and Schwann cells, and Schwann cell precursors and Schwann cells generated by such methods. The presently disclosed subject matter also provides for uses of such Schwann cell precursors and Schwann cells for regeneration of PNS and/or CNS, for prevention and/or repair of myelin damages, and/or for prevention and/or treatment of Schwann cell related disorders (e.g., peripheral neuropathy, e.g., Diabetic Peripheral Neuropathy).

A computerized method of generating a map of myelin tissue of a brain is described. In addition sub-maps of different myelin contents can be imaged. The method uses a simulation model comprising at least two interacting tissue compartments.

The invention provides application of an autophagy inducer serving as a microtubule stabilizing drug to the promotion of nerve regeneration. Specifically, the invention provides a method for promotingthe enation of in vitro culture central neuron and weakening the inhibiting effect on enation by myelin, or stabilizing microtubules central nervous damaged nerve cells, or reducing retracement or formation of retracement vesicles after a central nerve axon is damaged, or promoting axon regeneration after central nervous is damaged, and the method comprises the step of ensuring that an ex vivo nerve cell is in contact with the autophagy inducer, so as to induce autophagy. The invention further provides application of the autophagy inducer to drug preparation. By adopting the method, axon retracement can be obviously reduced after medulla spinalis is damaged, and axon regeneration and the recovery of a movement function can be promoted.

A method of generating a cell that enhances functional myelin production is provided, the method including genetically modifying the cell such that: (i) an endogenous PLP1 gene is modified to decrease its ability to inhibit myelin production; (ii) an endogenous PLP1 genetic regulatory element is modified to decrease its ability to promote PLP1 expression; (iii) an endogenous PLP1 genetic regulatory element is modified to increase its ability to inhibit PLP1 expression; or (iv) an endogenous PLP1 gene product or a PLP1 regulatory element gene product that promotes PLP1 expression is modified to decrease the PLP1 expression level, wherein the cell produces functional myelin.

The invention relates to the field of biotechnology, and particularly relates to application of an EGFR/ERK/TRIM32 signal path in promoting differentiation of spinal nerve stem cells after spinal cordinjury. According to the application, inhibitors or blockers of the EGFR/ERK/TRIM32 signal path and TRIM32 can be used for promoting the differentiation of the neural stem cells into neurons during the spinal cord injury repair process. After the spinal cord injury, a myelin protein finally inhibits a downstream target TRIM32 protein by activating the EGFR/ERK signal path, and further inhibitingthe differentiation of the neural stem cells into the neurons. The EGFR/ERK/TRIM32 signal path can be used as a new drug target for the spinal cord injury repair, and provides new ideas for repair andtreatment of the spinal cord injury repair.

A method for curing mild Multiple Sclerosis, memory impairment and Seasonal Affective Disorder. An Applied Kinesiology technique, used to desensitize a patient to allergies, is used to desensitize a patient to myelin and melatonin. Desensitizing the patient to myelin and melatonin cures mild Multiple Sclerosis, memory impairment and Seasonal Affective Disorder.